Skip to content

Effectiveness evaluation of intra-ovarian injection of autologous menstrual blood stem cells in fertility potential of patients with poor ovarian response: a controlled clinical trial study

Effectiveness evaluation of intra-ovarian injection of autologous menstrual blood stem cells in fertility potential of patients with poor ovarian response: a controlled clinical trial study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180619040147N4
Enrollment
180
Registered
2020-08-01
Start date
2020-06-21
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poor ovarian response. Asymptomatic postprocedural ovarian failure

Interventions

Intervention 1: Intervention group: includes 90 patients with poor ovarian response that will be treated by once injection of autologous menstrual blood stem cells. After cells isolation, culture and

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 45 Years

Inclusion criteria

Inclusion criteria: married women ages between 25-45 years old Picked up equal or less than 3 oocytes in last ovarian stimulation Anti mullerian hormone; less than 1.1 nanogram per milliliter Anteral follicles: less than 5-7 Spermogram: more than 5 million per millilieter normal morphology more than 1%

Exclusion criteria

Exclusion criteria: un treated Thyroid dysfunction Immune disorders History of cancer, chemotherapy and radiotherapy Infected by hepatitis B,C or HIV Severe endometriosis History of ovarian surgery Diabetes Dysfunction of electrolyte or liver tests Psychological problem like depression, high stress an anxiety renal failure disease history of blood trasfusion, anemia or sickle cell anemia

Design outcomes

Primary

MeasureTime frame
Number of antral follicles in ovary. Timepoint: Before intervention, 3 months and 6 months after cell administration. Method of measurement: Vaginal sonography.;Anti Mullerian hormone level in blood serum. Timepoint: Before intervention, 3 months, 6 months and one year after cell administration. Method of measurement: biochemical assay.;Number and quality of oocytes in intra-cytoplasmic sperm injection cycle. Timepoint: first intra-cytoplasmic sperm injection cycle after intervention. Method of measurement: embryologic evaluation.;Spontaneous pregnancy. Timepoint: up to 3 months after intervention. Method of measurement: beta-HCG assay.

Secondary

MeasureTime frame
Implantation rate. Timepoint: in new intra-cytoplasmic sperm injection cycle after intervention. Method of measurement: Vaginal sonography.;Clinical pregnancy. Timepoint: 6-8 weeks after last menstrual period. Method of measurement: Vaginal sonography.;Live birth. Timepoint: 9 months after pregnancy. Method of measurement: delivery report based on gynecologist comment.;Embryo quality and number. Timepoint: in new intra-cytoplasmic sperm injection cycle after intervention. Method of measurement: embryology report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomaieh Kazemnejad

Iranian academic center for education culture and research

kazemnejad_s@yahoo.com+98 21 2243 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026